Relevance of CYP3A5 Expression on the Clinical Outcome of Patients With Renal Cell Carcinoma
| Autor: | Koichi Takeuchi, Masachika Fujiyoshi, Koichiro Wada, Yumi Kotera, Hideo Ueki, Noritaka Ariyoshi, Yasutomo Nasu, Shogo Watari, Jun Matsumoto, Toshihiro Koyama |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Oncology Cancer Research Prognostic factor medicine.medical_specialty Mrna expression renal cell carcinoma treatment outcome Normal tissue Disease-Free Survival Polymorphism (computer science) Renal cell carcinoma Internal medicine Cytochrome P-450 CYP3A Humans Medicine In patient human CYP3A5 Carcinoma Renal Cell Aged Aged 80 and over Messenger RNA business.industry General Medicine Middle Aged Prognosis medicine.disease Gene Expression Regulation Neoplastic Treatment Outcome cytochrome P450 CYP3A Female business |
| Zdroj: | Anticancer Research. 41:2511-2521 |
| ISSN: | 1791-7530 0250-7005 |
| DOI: | 10.21873/anticanres.15029 |
| Popis: | Background/Aim: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). Patients and Methods: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. Results: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. Conclusion: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|